Yi Han1, Surya Ayalasomayajula2, Wei Pan1,3, Fan Yang1, Yaozong Yuan4, Thomas Langenickel5, Markus Hinder5, Sampath Kalluri6, Parasar Pal6, Gangadhar Sunkara7. 1. Translational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, Shanghai, China. 2. Translational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. surya.ayalasomayajula@novartis.com. 3. Shanghai Roche Pharmaceuticals Ltd., Shanghai, China. 4. Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 5. Translational Medicine, Clinical Pharmacology and Profiling, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland. 6. Biostatistical Sciences, Novartis Healthcare Private Limited, Hyderabad, India. 7. Translational Medicine, Drug Metabolism and Pharmacokinetics, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.
Abstract
BACKGROUND AND OBJECTIVE:Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several countries for the treatment of patients with heart failure and reduced ejection fraction. This was the first study conducted to characterise the pharmacokinetics of LCZ696 analytes (pro-drug sacubitril, active neprilysin inhibitor LBQ657 and valsartan) after single-dose administration of LCZ696 in healthy Chinese subjects. METHODS: In this open-label, randomised, parallel-group study, following screening and baseline evaluation, eligible healthy subjects received single oral doses of LCZ696 50, 100, 200 or 400 mg. The pharmacokinetics, safety and tolerability of LCZ696 were assessed up to 72 h after dosing. A total of 40 healthy male subjects were enrolled, and all completed the study. RESULTS: Following oral administration, LCZ696 delivered systemic exposure to sacubitril, LBQ657 and valsartan with a median time to reach maximum plasma concentration (T max) ranging from 0.50 to 1.25, 2.00 to 3.00 and 1.50 to 2.50 h, respectively, over the investigated dose range. The mean terminal elimination half-life (T 1/2) ranged from 0.89 to 1.35, 8.57 to 9.24 and 5.33 to 7.91 h for sacubitril, LBQ657 and valsartan, respectively. The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last), and maximum plasma concentration (C max) for LBQ657 increased dose proportionally over the entire dose range. Dose linear increase in the exposure was observed across the dose range for sacubitril and valsartan. LCZ696 was safe and well tolerated at all doses in this study. Adverse events of only mild intensity, which required no treatment, were reported in 6 (15 %) subjects. CONCLUSION: The pharmacokinetic profiles of LCZ696 analytes in Chinese subjects are similar to those reported previously in Caucasian subjects.
RCT Entities:
BACKGROUND AND OBJECTIVE:Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) and has been recently approved in several countries for the treatment of patients with heart failure and reduced ejection fraction. This was the first study conducted to characterise the pharmacokinetics of LCZ696 analytes (pro-drug sacubitril, active neprilysin inhibitor LBQ657 and valsartan) after single-dose administration of LCZ696 in healthy Chinese subjects. METHODS: In this open-label, randomised, parallel-group study, following screening and baseline evaluation, eligible healthy subjects received single oral doses of LCZ696 50, 100, 200 or 400 mg. The pharmacokinetics, safety and tolerability of LCZ696 were assessed up to 72 h after dosing. A total of 40 healthy male subjects were enrolled, and all completed the study. RESULTS: Following oral administration, LCZ696 delivered systemic exposure to sacubitril, LBQ657 and valsartan with a median time to reach maximum plasma concentration (T max) ranging from 0.50 to 1.25, 2.00 to 3.00 and 1.50 to 2.50 h, respectively, over the investigated dose range. The mean terminal elimination half-life (T 1/2) ranged from 0.89 to 1.35, 8.57 to 9.24 and 5.33 to 7.91 h for sacubitril, LBQ657 and valsartan, respectively. The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last), and maximum plasma concentration (C max) for LBQ657 increased dose proportionally over the entire dose range. Dose linear increase in the exposure was observed across the dose range for sacubitril and valsartan. LCZ696 was safe and well tolerated at all doses in this study. Adverse events of only mild intensity, which required no treatment, were reported in 6 (15 %) subjects. CONCLUSION: The pharmacokinetic profiles of LCZ696 analytes in Chinese subjects are similar to those reported previously in Caucasian subjects.
Authors: Thorir D Bjornsson; John A Wagner; Stephen R Donahue; Dawn Harper; Aziz Karim; Marlene S Khouri; William R Murphy; Kristin Roman; Dennis Schneck; Daryl S Sonnichsen; Dennis J Stalker; Stephen D Wise; Stuart Dombey; Caroline Loew Journal: J Clin Pharmacol Date: 2003-09 Impact factor: 3.126
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Sheng Shou Hu; Ling Zhi Kong; Run Lin Gao; Man Lu Zhu; Wen Wang; Yong Jun Wang; Zhao Su Wu; Wei Wei Chen; Ming Bo Liu Journal: Biomed Environ Sci Date: 2012-06 Impact factor: 3.118
Authors: Pardeep S Jhund; Brian Claggett; Milton Packer; Michael R Zile; Adriaan A Voors; Burkert Pieske; Martin Lefkowitz; Victor Shi; Toni Bransford; John J V McMurray; Scott D Solomon Journal: Eur J Heart Fail Date: 2014-04-01 Impact factor: 15.534